Buy HIMS by Mar 9, 2029.

Interesting development in the telehealth space. Hims & Hers ($HIMS) surged roughly 40% in a single day after announcing a partnership with Novo Nordisk that will allow the company to offer Ozempic and Wegovy through its platform. These GLP-1 drugs have quickly become some of the most in-demand pharmaceuticals globally, driven by their effectiveness for both diabetes and weight loss. For Hims, the agreement potentially opens the door to a major new revenue stream tied to one of the fastest-growing …